Clinical Trial Update: Germline DNA-Based Radiosensitivity Biomarker Influence on Toxicity Following Prostate Radiotherapy, GARUDA Trial [NA]

View source ↗

Summary

The GARUDA trial update describes ongoing research on how germline DNA-based radiosensitivity biomarkers may influence toxicity from prostate radiotherapy; the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Snippet

Sponsor: Jonsson Comprehensive Cancer Center | Conditions: Prostate Adenocarcinoma, Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8 | NA | Status: ACTIVE_NOT_RECRUITING